Aging, Annals Internal Medicine, Author Interviews, NIH, Nutrition / 01.09.2022
Tea Drinkers May Live Longer
MedicalResearch.com Interview with:
[caption id="attachment_59475" align="alignleft" width="150"]
Dr. Maki Inoue-Choi,[/caption]
Maki Inoue-Choi, Ph.D., M.S., R.D.
Staff Scientist
Metabolic Epidemiology Branch
National Institutes of Health
MedicalResearch.com: What is the background for this study?
Response: Tea is rich in bioactive compounds that can possibly protect against health conditions such as cancer and heart disease. A lower risk of death was seen among tea drinkers than non-drinkers in previous studies, but these were largely in populations where green tea drinking is common. In contrast, the studies in populations where black tea drinking is more common have been limited and the findings from these studies have been inconsistent.
Dr. Maki Inoue-Choi,[/caption]
Maki Inoue-Choi, Ph.D., M.S., R.D.
Staff Scientist
Metabolic Epidemiology Branch
National Institutes of Health
MedicalResearch.com: What is the background for this study?
Response: Tea is rich in bioactive compounds that can possibly protect against health conditions such as cancer and heart disease. A lower risk of death was seen among tea drinkers than non-drinkers in previous studies, but these were largely in populations where green tea drinking is common. In contrast, the studies in populations where black tea drinking is more common have been limited and the findings from these studies have been inconsistent.
Shuchi Anand, MD MS (she/her)
Assistant Professor in Medicine
Director, Center for Tubulointerstitial Kidney Disease
Stanford University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: A majority of people on dialysis who completed vaccination as of September 2021 have had a decline in antibody response to levels that would render them vulnerable to infection. Antibody response immediately after vaccination and circulating antibody response is strongly associated with risk for breakthrough after the initial vaccination series.